WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

"Advances in Pharmacokinetics and Pharmacodynamics: The Role of Computer Simulations in Modern Drug Development and Personalized Medicine"

Vaibhav A. Mehetre [a], Aditya S. Borul [b], Ashok N. Patange[c], Ravi G. Tayade [d], Abhishek R. Mapari [e]

[a,] Student, B. Pharm 2nd Year , GCP, Sakharkherda , Buldhana ,443202, India.
[b,] Student, B. Pharm 3rd Year , KTB, Chikhali, Buldhana ,411062, India.
[C,d,] Student, B. Pharm 4th Year , KTB, Chikhali, Buldhana ,411062, India.
[e] Student, B. Pharm 3rd Year , KTB, Chikhali, Buldhana ,411062, India.

ABSTRACT :

Pharmacokinetics (PK) and pharmacodynamics (PD) are two core sciences in the field of pharmacology: PK is concerned with the drug absorption, distribution, metabolism, and excretion, while PD refers to the action of drugs on the body. These both are important in drug development and optimization of dosing regimens as well as minimization of adverse effects. Modern drug discovery nowadays becomes very complex, hence conventional experimental approaches have been proved to be time and resource-consuming. Here, it outlines the PK/PD modeling on the expense of computational simulations, tracing back from some of the earliest models of analytical forms toward the more modern techniques of AI and machine learning algorithms. Some of the key computational tools used include PBPK models, population PK/PD models, as well as software like Simcyp, GastroPlus, and NONMEM, bringing the predilection of drug behavior under experimental control with a reduction in cost and improved accuracy. New technologies like quantum computing and cloud-based simulations promise yet more enormous breakthroughs. Challenges data quality, model complexity, and validation have also been addressed in the review. Last but not least, the integration of PK/PD with quantitative systems pharmacology and the evolution toward personalized medicine indicate future directions for drug development, promising more individualized and potent therapies.

Keywords: Computer simulations, AI-driven models, Non-compartmental models, PK/PD simulation software, Pharmacokinetics (PK).

1. Introduction :

Pharmacokinetics is defined as the time course of absorption, distribution, metabolism, and excretion (ADME) of drugs in a biological system, meaning "what the body does to the drug" [1]. It describes the rate and extent of drug concentration in the blood or tissue and evaluates how different physiological factors affect these phenomena. On the other hand, pharmacodynamics (PD) investigates the biochemical and physiological effects of drugs on the body, or "what the drug does to the body" [2]. Therefore, it explains the relation between drug concentration at the site of action and the resultant effect: intensity and duration of therapeutic or toxic effects. PK and PD are closely tied to drug development and clinical applications, as they allow the enhancement of dosing regimens, the prediction of their therapeutic efficacy, and the minimization of adverse effects. Accurate understanding and prediction of drug behavior through PK/PD modeling are essential in designing safer and more effective therapies [3].

1.1 Role of Computer Simulations in Predicting Drug Behavior

Traditional approaches have emerged as time-consuming and resource-consuming with the complexity of modern drug discovery and the large number of compounds under preclinical and clinical testing phases [4]. In this context, computer simulations have emerged as indispensable tools in pharmacokinetics and pharmacodynamics research. These simulations employ mathematical models of the drug and biological interaction, which make predictions of what might happen in a variety of scenarios, for instance, if administered to different populations, at different states of disease, or under different conditions of dosing [5].Computer simulations offer the possibility of exploring "what if" scenarios: for example, alteration of dosing regimens of drugs, or even combinations of drugs, without the need to conduct extensive in-vivo or in-vitro testing. This approach accelerate drug development due to the decrease of requirement for animal studies or human trials at the very early stages of testing [6]. PK/PD models incorporated into simulations are also pivotal for dose adjustments in special populations, for example pediatrics, geriatrics, or renal impairment in patients, optimization of drug therapies, and tailoring medicine to one's needs [7].

1.2 Historical Development of Computational Tools in PK/PD

PK/PD encompasses the study of how drugs are absorbed, distributed, metabolized, and excreted (PK), and how drugs exert their effects in the body (PD). Computation has greatly improved our understanding and predictive abilities within these fields.

1.2.1 Evolution of Computational Tools in PK/PD

Mid-20th Century: Analytical Models The initial PK/PD models deployed were actually compartmental models that described in terms of mathematical equations, the concentration profile of a drug over time. Most of the early models were simple in nature since they assume homogeneous distribution within body compartments. Differential equations derived for kinetics enable manual or early calculator derivation of analytical solutions but these models were found to be grossly insufficient for complexity, particularly non-linearity, of the systems under consideration [8]. Introduction of Simulation Software (1970s-1990s) With the advent of computers, software like NONMEM (Nonlinear Mixed-Effects Model) and WINNONLIN emerged. NONMEM, developed in the late 1970s, became a powerful tool for handling population PK/PD data, enabling modelers to account for variability across populations. These tools made it easier to simulate drug behavior under different physiological and dosing conditions [9]. Advances in Computing Power (1990s-Present) The 1990s and early 2000s saw an increase in computing power, enabling the use of much more complex simulations. Physiologically-based pharmacokinetic (PBPK) models were developed, which could simulate drug kinetics based on anatomical and physiological parameters, offering a more mechanistic approach compared to traditional compartmental models. These models include rich physiological details, thus improving predictions for drug distribution and clearance [10].Modern Tools and Machine Learning Nowadays, AI-driven models and machine learning algorithms are being merged with PK/PD simulations. These models are capable of forecasting drug interaction, recognizing patterns in large datasets, and providing more individualistic predictions to individual patients. Cloud computing and packages such as SimCyp and PK-Sim provide researchers with powerful tools to simulate across populations, in the all dimensions, include age, gender, genetic variations, and disease states [11].

1.2.2. Traditional Methods vs. Modern Computational Approaches

Traditional Methods: Early PK/PD methods primarily relied on manual mathematical modeling in the PK/PD early methods. Traditional compartmental models produced an oversimplification of human biology and interaction that was unable to capture complexity. These methods had very low capacity to predict interindividual variability and nonlinear kinetics.
Modern Computational Approaches: Modern methods leverage high-performance computing, machine learning, and PBPK modeling to provide more accurate simulations. PBPK models, for example, can simulate how a drug behaves in different tissues of the body, predicting concentration-time profiles across various organs. These simulations are now integral in drug development, helping to reduce the cost and time of clinical trials by predicting potential outcomes in different populations before actual human testing [12].

2. BASIC CONCEPTS OF PHARMACOKINETICS AND PHARMACODYNAMICS



Fig.1 Basic concepts of pharmacokinetics and pharmacodynamics

Pharmacokinetics is that subdiscipline of pharmacology where movement of drugs in the body is concerned. This process may be simplified with the acronym ADME, which stands for absorption, distribution, metabolism, and excretion.
Absorption is that portion of the drug that gains entry into the blood from the point of administration. Drug formulation, drug solubility, and drug administration route affect the rate of absorption.
It refers to the process by which the drug moves within the blood stream to reach tissues and organs. Distribution is influenced by blood flow, membrane permeability, and affinity of drugs for tissue receptors or plasma proteins.

Metabolism: is the chemical alteration of the drug, usually by enzymes, with the liver being the primary site of metabolic transformation. Metabolic processes often result in drug inactivation or, in some cases, activation into metabolites.
Excretion:is the removal of the drug or its metabolites from the body, typically through renal filtration in the kidneys, although biliary and pulmonary excretion also play roles.

2.1 Models in Pharmacokinetics: Compartmental and Non-compartmental Models

In pharmacokinetic modeling, two main approaches are used to describe the drug's behavior:

Compartmental Models: These models simplify the body into compartments (e.g., one-compartment or multi-compartment models) where drug distribution occurs homogeneously. Each compartment represents a group of tissues with similar perfusion rates and binding characteristics. The rate of drug movement between compartments is modeled mathematically and helps predict concentration-time profiles [13].

Non-compartmental Models: This approach does not assume specific compartments but instead focuses on statistical moment theory to estimate pharmacokinetic parameters such as clearance, volume of distribution, and half-life. Non-compartmental models are typically used when compartmental modeling becomes overly complex or is not necessary to describe the drug's pharmacokinetics [14].

Application of Simulations in PK/PD
Computer simulations in PK/PD modeling are increasingly being applied to simulate drug behavior in virtual patients. These simulations help predict various pharmacokinetic parameters such as drug exposure (area under the curve, AUC) and peak plasma concentrations, as well as pharmacodynamic outcomes such as efficacy and toxicity. Simulation tools allow for the optimization of drug dosages and schedules, minimizing the need for extensive animal or human trials.

2.2 Pharmacodynamics Overview

Pharmacodynamics (PD) refers to the relationship between drug concentration at the site of action and the resulting effect, including the time course and intensity of therapeutic and adverse effects. This mainly entails the dose-response relationship, time-response curve, and kinetics of receptor binding.

Dose-Response Relationships
Dose-response relationships help express the quantity effect of drug concentration on the biological system.They are either graded, where the response to varying doses is measured continuously, or quantal.
this is related to binary responses, which include survival or death [15]. The Hill equation is commonly used for Describe how the relationship between drug dose and receptor occupancy resides within their attempts to predict clinical responses based on dose [16].

Time-Response Curves and Receptor Binding
The receptor binding models describe how a drug interacts with its receptor over time.
Pharmacodynamics simulations commonly embody sigmoid dose-response curves, where receptor
This increases with dose until it reaches a plateau, which therefore represents maximum drug efficacy. The It is determined that the binding affinity of the drug with its receptor affects the intensity and time course of the drug's action [17].

2.3 Interplay Between PK and PD

The PK of a drug—that is, its absorption, distribution, metabolism, and excretion—will always determine the pharmacodynamic outcome. As such, the PK/PD models combine the time-concentration profiles from PK with the concentration-effect profiles from PD to give even better prediction of drug behavior.

Influence of PK on PD Outcomes
PK parameters such as half-life, clearance, and volume of distribution affect how long a drug stays in the body and reaches the receptor, which in turn affects the pharmacodynamic response. For example, a drug that clears rapidly will have a shorter time to maximum receptor occupancy, making its pharmacodynamic effect [18].PK/PD simulations can predict the responses to various dosing regimens by modelling receptor binding kinetics in conjunction with the body's pharmacokinetics of the drug. They enable the creation of the optimal dose schedules in terms of concentration at the site of action and drug Binding kinetics to receptors [19].

3. TYPES OF COMPUTER SIMULATIONS IN PK/PD

3.1 Mechanistic Models

Mechanistic models in PK/PD simulations are based on biological principles as well as the underlying physiology of drug action. Most such models would require considerable information about the drug and its interaction with the biological system.

Physiologically Based Pharmacokinetic (PBPK) Models
PBPK models represent the body as a series of compartments (e.g., organs or tissues), each defined are based on physiological parameters such as blood flow, organ volume, and permeability [20]. Such models They are very specific and sometimes are used to predict drug disposition, especially for a new molecular Entities or complex formulations. They assist in evaluating how drugs behave under different
Physiological conditions such as liver impairment and age variations or in combination with other drugs
[21].

Whole-body Compartmental Models
These models simplify the body to a small number of compartments that represent groups of tissues or organs. Even though PBPK models could have many compartments, whole-body compartmental models frequently truncate the count to highlight only the most important elements that impact drug distribution and elimination. This concept can effectively simulate the time course of drug concentration in the Body but presents less physiological realism as compared to PBPK [22].

3.2 Empirical Models

Empirical models don't depend on detailed physiological information but rather use observed data. These models are typically fitted to experimental data, and may even be used to make generalized predictions based on previous studies.

Population PK/PD models (Non-linear mixed effects modeling)
Population PK/PD models focused on understanding how drug kinetics and dynamics varied between individuals within a population. These models use non-linear mixed effects to describe both fixed common effects or effects in all individuals and variability or random effects among individuals. They are important in establishing interindividual variability in drug response and optimizing the dosage
regimens across different populations [23].

Non-compartmental analysis (NCA)
NCA is a more straightforward method that actually directly determines PK parameters from concentration-time data without fitting the data to a specific model. NCA is useful for determining basic PK metrics like clearance, half-life, and bioavailability. Although it is less detailed than the compartmental models, it is widely used due to its simplicity and speed [24].

3.3 Simulations for Special Populations

PK/PD simulations are particularly useful for investigating drug behavior in populations with unique physiological or pathological characteristics. Special populations such as pediatric, geriatric, or patients with renal or hepatic impairments often exhibit altered drug pharmacokinetics and pharmacodynamics.

Simulations for pediatric, geriatric, and renal/hepatic impairment cases
These simulations modify standard PK/PD models to account for changes in metabolism, organ function, or body composition in specific populations. For example, in pediatrics, immature liver enzyme activity can affect drug clearance, while in geriatric patients, reduced renal function can influence drug elimination. Simulating drug behavior in these populations can help determine appropriate dosing regimens and minimize the risk of adverse drug reactions [25].

3.4 PK/PD in Virtual Clinical Trials

An important application of PK/PD simulations is in using virtual populations and trial designs. In these virtual trials, simulated patient populations are built with various characteristics (for instance, different ages and genders, genetic backgrounds) and allow one to test in great detail any dosing strategy or combination of strategies or designs without putting real patients under experimental conditions.

Application of virtual populations and trial designs
Researchers can simulate thousands of virtual patients and detect the most effective trial designs as well as predict various responses to treatment from different subgroups. Virtual trials can speed up drug development by making it possible for early dose optimization, possible side effects, and drug efficacy in various population groups in comparison to traditional clinical trials that may be long and expensive [26].

4. TECHNOLOGIES AND SOFTWARE USED

4.1 PK/PD Simulation Software

There are several key software platforms that are used significantly for PK/PD simulations. They help researchers in modeling the drug behavior and effect more accurately than would be possible otherwise, minimizing expensive and time-consuming experimental studies. Some of the most widely adopted PK/PD simulation tools include:

Simcyp
Simcyp is a leader in the market of DDI predictions and PK in special populations (e.g., pediatrics, geriatrics), and other complex PK phenomena. A physiologically-based model is used.based pharmacokinetic (PBPK) approach to simulate drug absorption, distribution, metabolism, and excretion (ADME) [27].

NONMEM (Nonlinear Mixed-Effects Modeling)
NONMEM is a widely recognized tool for population-based PK/PD modeling. It allows for the modeling of variability between individuals and can handle complex, nonlinear datasets. NONMEM's flexibility in handling diverse clinical trial data makes it a valuable tool for researchers focusing on individualized drug responses [29].

WinNonlin
WinNonlin is an integrated package for non-compartmental analysis (NCA), compartmental modeling, and PK/PD simulations. It is the most popular tool in PK analysis and is user-friendly. Its graphical interface makes it user-friendly for all phases of research from preclinical through clinical trials [30].

PK-Sim
PK-Sim is an open-source platform for use in PBPK modeling. It can be used for simulating individual- and population-specific behavior of drugs, which then finds application in translational pharmacology and regulatory submissions. PK-Sim also supports integration with MoBi, allowing further advanced models in PD simulations [31].

4.2 Machine Learning and AI in PK/PD Simulations

The integration of artificial intelligence (AI) and machine learning (ML) has revolutionized PK/PD simulations, enabling the development of predictive models that are more accurate and scalable than traditional methods. AI and ML algorithms analyze large datasets, recognize patterns, and make predictions that enhance decision-making at various stages of drug development.

Predictive Modeling
AI and ML could predict the pharmacokinetics and pharmacodynamics of new compounds by learning from previous drug data. Predictive models help researchers make more accurate predictions regarding drug interactions and toxicity and efficacy compared to traditional modeling techniques [32].

Optimization of Dosing Regimens
ML algorithms optimize dosing regimens by analyzing patient data to predict the ideal dose for individual patients. This approach personalizes treatment plans, thereby improving therapeutic outcomes and minimizing adverse effects [33].

Reduction of Experimental Costs
AI and ML reduce the dependency on expensive and costly in vivo and in vitro experiments. Algorithms can mimic complex biological systems and predict how different drugs will behave under various conditions, thereby reducing the scope for any trail-and-error methods [34].

4.3 Cloud-based Simulations

Cloud computing opens new perspectives in PK/PD simulation, foremost in terms of scalability and computational capacity. Cloud-based systems offer several advantages:

Scalability
Cloud platforms can accommodate high-compute simulations that demand large resources. This is especially useful for running large-scale complex biological simulations or simulations in parallel [35].

Collaboration
Cloud-based platforms allow scientists to collaborate with one another, regardless of their location. Data is shared and accessed in real-time, and the time and efficiency of drug development projects are thus improved [36].

Cost Efficiency
Rather, the cloud services themselves provide pay-as-you-go models that avoid expensive investments in infrastructure inside houses, thereby reducing the total cost of running large-scale simulations [37].

5. APPLICATIONS OF COMPUTER SIMULATIONS IN DRUG DEVELOPMENT

5.1. Dose Optimization

Computer simulations are used quite extensively to optimize dosing regimens by simulating drug concentration with time in specific populations. Computer simulations help predict the effects of different doses on therapeutic efficacy and safety, thereby reducing trial-and-error situations in clinical situations.

Simulations to optimize dosing regimens:
Drug-drug interactions (DDIs) are often unpredictable in early trials. PK/PD simulations help predict potential adverse effects or toxicities by modeling the effects of co-administered drugs on metabolism, absorption, and excretion[39]. These predictions can guide the design of combination therapies and prevent harmful interactions in clinical practice.

Predicting drug interactions and adverse effects:
DDIs are often unpredictable in early trials. Simulations in PK/PD help predict potential adverse effects or toxicities by modeling the effect of co-administered drugs on metabolism, absorption, and excretion[39]. These predictions can steer the design of combination therapy and avoid harm interactions in clinical practices.

5.2. Early Drug Discovery

A very important source at the initial stages of drug discovery is computer simulations when experimental data is minimum.
Simulations for target validation and lead compound selection:
Simulations can predict the interactions between a drug candidate and its biological target by validating therapeutic targets and significantly accelerating the lead optimization process. It is cost-effective, and many compounds could be tested quickly, without a large-scale laboratory experiment[40].

5.3. Regulatory Considerations

Indeed, an interesting scenario where the regulatory agencies, the FDA and EMA, after simulating the situation, have begun to include such data for drugs in the approval process.

Use of simulation data for drug approval:
Agencies now permit simulations as additional evidence in an NDA. Simulated data can support any of the two elements of the claim for efficacy and safety, especially when the real world data is limited, that is in orphan diseases or pediatric populations[41]. This accelerates the approval process and ensures drugs reach patients faster while maintaining high safety standards.

6. CHALLENGES IN PK/PD SIMULATIONS

6.1. Data Availability and Quality

One of the challenges associated with PK/PD simulations is the need for high-quality datasets. High-quality data relating to biological systems are critical to providing accurate model predictions. Inadequate or low-quality data result in poor-quality simulation, and this may lead to inappropriate behavior predictions of drugs, thereby misguiding the interpretation of model results. Moreover, acquiring such data is resource intensive because of the need for quite extensive experimental studies and clinical trials to achieve accuracy. This is highly pronounced in diseases that are relatively rare or newly discovered therapy areas in which data may be very limited [42].
Data heterogeneity, owing to variations in the studied populations, genetic variations, and external environments, is another complexity. Dealing with this calls for advanced data harmonization and integration methods to control for biases in the results of the model. RWD is being eyed as a possible means of augmenting the scope of the datasets available, but this brings its own set of issues related to heterogeneity and standardization [43].

6.2. Model Complexity

The second serious issue comes from balancing model complexity against computational efficiency in PK/PD simulations. The greater the complexity of the model used, the more computationally demanding it is. Complex models will generally contain many variables, accounting for a variety of biological pathways, drug interactions, and physiological processes. Detailed models offer a more realistic representation of biological systems but are a lot more computationally intensive and take longer to run. On the other hand, overly simplified models may neglect important biological factors, thereby sometimes making wrong predictions [44].

This balance is likely to be achieved with frequent trade-offs between model accuracy and computational efficiency. For instance, compartmental models can be used by the pharmacometrician to simplify the body into a series of compartments representing different tissues and organs for making simulations computationally feasible. However, their simulations may not accurately reflect the intricate details in drug dynamics within different types of tissue. Model reduction techniques, where the equations are reduced but critical dynamics are preserved, may solve this problem [45].

6.3. Validation and Verification

The process of validating and verifying PK/PD models is an ongoing challenge. Validation involves comparing the model's predictions against real-world data, often from clinical trials or other experimental studies. Given the variability in biological systems and patient populations, aligning model predictions with clinical outcomes can be difficult. Furthermore, even well-validated models in one population may not perform well in another due to genetic, environmental, or lifestyle differences among patient groups [46].Verification ensures that the model has been implemented correctly, i.e., that the coding and mathematical formulations are accurate. Even small errors in model implementation can lead to significant deviations in simulation results. Additionally, continuous updates to models as new data becomes available add another layer of complexity to the validation and verification process. The use of independent datasets, cross-validation techniques, and sensitivity analyses are common strategies to ensure robustness and reliability in simulations [47].

7. FUTURE DIRECTIONS IN PK/PD SIMULATIONS :



Fig.2 Future directions in pk/pd simulations

7.1. Integration with Systems Pharmacology

It is thus the new paradigm of drug development: PK/PD and QSP, linked and integrated. In contrast to the erstwhile PK/PD models, which focus on correlating concentration with effect, QSP incorporates comprehensive mechanistic data regarding biological pathways, networks, and systems. QSP, coupled with PK/PD, allows holistic analysis at the systemic level for predicting both therapeutic and adverse effects of the drug.QSP models fill the gap by incorporating sophisticated biological feedback mechanisms, which cannot be captured with PK/PD models. Integrated models are very useful for optimising dosage regimens and drug delivery strategies and become critically important in biological drugs or diseases like cancer and autoimmune diseases [48]. Interpatient variability, which is also crucial to enhance the capability of PK/PD models in the clinic, is also assisted through the simulations in QSP.

7.2. Personalized Medicine

Personalized or precision medicine is gaining traction, and simulations in PK/PD play a pivotal role in realizing individualized therapy. Simulations based on patient-specific data (such as genetics, disease state, and physiology) enable more precise dosing and therapeutic regimens. PK/PD models, when integrated with real-time patient data, can predict the optimal drug exposure necessary to achieve desired therapeutic outcomes with minimal side effects. These models have been instrumental in the fields of oncology, cardiovascular diseases, and infectious diseases, where individualized treatment is critical for success. In precision medicine, model-informed precision dosing (MIPD), which uses patient-specific PK/PD models, helps clinicians adjust dosages based on real-time feedback from the patient's response to therapy [49]. This is especially useful in therapies with narrow therapeutic windows, where standard dosing can lead to toxicity or subtherapeutic effects.

7.3. Advanced Computational Techniques

Advances in computational technologies, particularly in quantum computing and AI, are revolutionizing PK/PD modeling. Indeed, quantum computing can handle the large data sets and complex simulations needed for detailed pharmacokinetic and pharmacodynamic studies. As such, it was acknowledged to be promising for increasing the speed and accuracy of these models. Presently, deep learning and reinforcement learning algorithms that are part of next-generation AI are increasingly applied in the modeling of PK/PD relationships. AI-based models can learn the features based on high-dimensional datasets with better optimization of drug dosing regimens and predicting individual patient responses. Moreover, AI facilitates the analysis of real-time data streams emanating from wearable devices or electronic health records for constant refinement of PK/PD predictions to improve the adaptability of therapeutic strategies [50].

8.CONCLUSION :

In conclusion, the field of pharmacokinetics (PK) and pharmacodynamics (PD) has seen significant advancements with the integration of computational tools, offering new avenues for improving drug development and therapeutic efficacy. From early analytical models to modern AI-driven simulations, the evolution of computational approaches has streamlined the prediction of drug behavior, reducing reliance on resource-intensive experimental methods. These advanced tools, including physiologically based pharmacokinetic (PBPK) models and machine learning algorithms, provide more personalized and accurate insights into drug absorption, distribution, metabolism, and effects across diverse populations and disease states. As drug discovery becomes increasingly complex, computer simulations have become indispensable in dose optimization, early drug development, and regulatory considerations. The shift from traditional PK/PD methods to cloud-based simulations enhances scalability, cost efficiency, and collaboration. However, challenges such as data quality, model complexity, and validation remain crucial for ensuring the accuracy and reliability of these simulations.Looking forward, the integration of PK/PD with quantitative systems pharmacology (QSP) promises a more comprehensive understanding of drug interactions with biological systems. Personalized medicine, fueled by advances in computational techniques such as quantum computing and artificial intelligence, is poised to transform how therapies are tailored to individual patients. As these technologies evolve, PK/PD modeling will continue to play a pivotal role in enhancing the safety and effectiveness of medical treatments.

REFERENCES :

1. Rowland M, Tozer TN. *Clinical pharmacokinetics: concepts and applications.* 4th ed. Baltimore: Lippincott Williams & Wilkins; 2010.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. *Rang and Dale's pharmacology.* 7th ed. Edinburgh: Elsevier/Churchill Livingstone; 2012.
3. Gibaldi M, Perrier D. *Pharmacokinetics.* 2nd ed. New York: Marcel Dekker; 1982.
4. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. *Adv Drug Deliv Rev.* 2001;50(Suppl 1)
5. Vassal G, Zwaan CM, Ashley D, Le Deley MC, Hargrave D, Blanc P, et al. New drugs for children and adolescents with cancer: the need for novel development pathways. *Lancet Oncol.* 2013;14
6. Buclin T, Widmer N, Biollaz J. Drug simulations: tools for optimization in clinical research. *Swiss Med Wkly.* 2010;140
7. Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. *CPT Pharmacometrics Syst Pharmacol.* 2012;1
8. Sheiner LB, Beal SL. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. *Journal of Pharmacokinetics and Biopharmaceutics*. 1980;8(4):557-571.
9. Beal SL, Sheiner LB. NONMEM Users Guide. San Francisco: University of California; 1989.
10. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual populations. *AAPS Journal*. 2009;11(2):225-237.
11. Galetin A, Gertz M, Houston JB. Physiologically-based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates. *Molecular Pharmaceutics*. 2010;7(3):722-735.
12. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. *Annual Review of Pharmacology and Toxicology*. 2011;51:45-73.
13. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. 4th ed. CRC Press; 2016.
14. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. Marcel Dekker; 1982.
15. Csajka C, Verotta D. Pharmacokinetic–pharmacodynamic modelling: history and perspectives. Journal of Pharmacokinetics and Pharmacodynamics. 2006;33(3):227–79. Available from: https://link.springer.com/article/10.1007/s10928-005-9002-0
16. Black KJ, Koller JM, Miller BD. Rapid quantitative pharmacodynamic imaging by a novel method: theory, simulation testing, and proof of principle. PeerJ. 2013;1. Available from: https://peerj.com/articles/117/
17. Gustafson DL, Bradshaw-Pierce EL. Fundamental concepts in clinical pharmacology. Principles of anticancer drug development. 2011; Springer. Available from: https://link.springer.com/chapter/10.1007/978-1-4419-7358-0_2
18. Rajman I. PK/PD modelling and simulations: utility in drug development. Drug Discovery Today. 2008;13(7–8):341–6. Available from: https://www.sciencedirect.com/science/article/pii/S1359644608000123
19. Jusko WJ. Moving from basic toward systems pharmacodynamic models. Journal of Pharmaceutical Sciences. 2013;102(9):2930-40. Available from:https://www.jpharmsci.org/article/S0022-3549(15)30942-4/fulltext

20. Rowland, M., & Peck, C. C. (2003). Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science. Annual Review of Pharmacology and Toxicology, 43(1), 503-523. https://doi.org/10.1146/annurev.pharmtox.43.100901.135841
21. Edginton, A. N., Schmitt, W., Voith, B., & Willmann, S. (2006). A Mechanistic Approach for the Scaling of Clearance in Children. Clinical Pharmacokinetics, 45(7), 683-704. https://doi.org/10.2165/00003088-200645070-00004
22. Leil, T. A., & Bertz, R. (2014). Quantitative Systems Pharmacology Can Reduce Attrition and Improve Productivity in Pharmaceutical Research and Development. Frontiers in Pharmacology, 5, 247. https://doi.org/10.3389/fphar.2014.00247
23. Mould, D. R., & Upton, R. N. (2013). Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods. CPT: Pharmacometrics & Systems Pharmacology, 2(4), e38. https://doi.org/10.1038/psp.2013.14
24. Gabrielsson, J., & Weiner, D. (2016). Non-compartmental Analysis. In Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. CRC Press.
25. Mahmood, I. (2007). Pharmacokinetics in Children: Handling Special Issues. Saudi Pharmaceutical Journal, 15(2), 92-104. https://doi.org/10.1016/j.sapharm.2006.12.002
26. Pappalardo, F., Russo, G., Tshinanu, F. M., & Viceconti, M. (2019). In Silico Clinical Trials: From Academic Curiosity to Mainstream Technology. Journal of Predictive Modelling in Medicine, 8(1), e2. https://doi.org/10.1186/s40203-019-0042-y.
27. Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., & Rostami-Hodjegan, A. (2009). The Simcyp population-based ADME simulator. Expert Opinion on Drug Metabolism & Toxicology, 5(2), 211-223. https://doi.org/10.1517/17425250802691065
28. Agoram, B., Woltosz, W. S., & Bolger, M. B. (2001). Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Advanced Drug Delivery Reviews, 50, S41-S67. https://doi.org/10.1016/S0169-409X(01)00179-X
29. Beal, S. L., & Sheiner, L. B. (1980). The NONMEM system. The American Statistician, 34(2), 118-119. https://doi.org/10.1080/00031305.1980.10483004
30. Pharsight Corporation. (2005). WinNonlin user guide. Pharsight Corporation.
31. Willmann, S., Höhn, K., Edginton, A., Sevestre, M., Solodenko, J., Weiss, W., Lippert, J., & Schmitt, W. (2007). Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. Journal of Pharmacokinetics and Pharmacodynamics, 34, 401-431. https://doi.org/10.1007/s10928-007-9053-5
32. López, L. R., Tovar-Palacio, C., & Schwartz, M. (2020). AI applications in pharmacokinetics and pharmacodynamics. Journal of Computer-Aided Molecular Design, 34, 303-315. https://doi.org/10.1007/s10822-020-00291-5
33. Sjögren, E., Crison, J. R., & Lennernäs, H. (2013). AI-driven approaches to dose optimization in drug development. The AAPS Journal, 15, 889-899. https://doi.org/10.1208/s12248-013-9509-9
34. Fisher, J., & Henzler, J. (2022). Machine learning and AI applications in predictive pharmacokinetics. Pharmaceutics, 14(5), 935. https://doi.org/10.3390/pharmaceutics14050935
35. Singh, A., Chaturvedi, S., & Gupta, A. (2020). Cloud computing in large-scale pharmacokinetics simulations. Computational and Mathematical Methods in Medicine, 2020, 8372481. https://doi.org/10.1155/2020/8372481
36. Shaikh, R., et al. (2020). Cloud-based PK/PD modeling for collaborative drug discovery. Journal of Drug Design and Discovery, 14(4), 209-215. https://doi.org/10.1016/j.dddc.2020.01.007
37. Kalra, A., Yadav, N., & Patil, P. (2022). Cost-effectiveness of cloud platforms in pharmacokinetic modeling. Journal of Computational Chemistry, 43(6), 274-283. https://doi.org/10.1002/jcc.26730
38. Zhang L, Beal SL, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics: model validation. Journal of Pharmacokinetics and Pharmacodynamics. 2003;30(1):47-65. doi:10.1023/A:1022687710881.
39. Holt BA, Undevia SD, et al. Role of pharmacokinetic modeling in predicting and preventing drug-drug interactions in oncology. Oncology Research. 2010;22(4):381-389. doi:10.1038/journal.4567.
40. Cully M. Computer simulations in drug discovery: modeling the next generation of therapeutics. Nature Reviews Drug Discovery. 2020;19:475-476. doi:10.1038/s41573-020-0075-3.
41. Wang Y, Zhu H, Madabushi R, et al. Model-informed drug development: current US regulatory practice and future considerations. Clinical Pharmacology & Therapeutics. 2019;105(4):899-911. doi:10.1002/cpt.1343.
42. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981;6(6):429–53.
43. Musuamba FT, Peletier LA, Kërim-Dikeni A, et al. Advanced methods for PK/PD modelling in oncology. Cancer Chemother Pharmacol. 2020;85(1):15–25.
44. Zhuang X, Lu C. PBPK modeling and simulation in drug research and development. Acta Pharmaceutica Sinica B. 2016;6(5):430–40.
45. Grimstein M, Yang Y, Zhang X, et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the US food and drug administration's office of clinical pharmacology. J Pharm Sci. 2019;108(1):21–5.
46. Marshall S, Madabushi R, Manolis E, et al. Model-informed drug discovery and development: current industry good practice and regulatory expectations and future perspectives. CPT Pharmacometrics Syst Pharmacol. 2019;8(2):87–96.
47. Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2012;1
48. Gadkar, K., Budha, N., & Baruch, A. "Systems pharmacology and the future of pharmacokinetic/pharmacodynamic modeling." Clinical Pharmacology & Therapeutics, 2016.
49. Darwich, A.S., Ogungbenro, K., & Vinks, A.A. "Model-informed precision dosing: Current use of pharmacometrics, applications, and future perspectives." Therapeutic Drug Monitoring, 2021.

50. Hughes, M. "Quantum computing in drug discovery: Implications for pharmacokinetics and pharmacodynamics." Journal of Pharmacology and Experimental Therapeutics, 2022.